Sanofi Aktie

74,40 EUR -0,46 EUR -0,61 %

09:58:10

STU

67,69 CHF +1,75 CHF +2,65 %

09:48:22

SWX

Sanofi jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.93,39 Mrd. EUR

KGV19,40Div. Rendite4,98%

WKN920657

ISINFR0000120578

SymbolSNYNF

Sanofi Aktien News

Sortieren:Datum Meistgelesen

25.06.24GlobeNewswirePress Release: Availability of the Q2 2024 Aide-mémoire

21.06.24GlobeNewswirePress Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee

21.06.24GlobeNewswirePress Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran

20.06.24GlobeNewswirePress Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa

12.06.24GlobeNewswireSanofi: Information concerning the total number of voting rights and shares – May 2024

06.06.24PR NewswireI-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

03.06.24GlobeNewswirePress Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3

31.05.24GlobeNewswirePress Release: Sanofi launches 2024 global Employee Stock Purchase Plan

31.05.24GlobeNewswirePress Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

31.05.24GlobeNewswirePress Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation

30.05.24GlobeNewswirePress Release: Sanofi completes acquisition of Inhibrx, Inc.

27.05.24GlobeNewswirePress Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma

21.05.24GlobeNewswirePress Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

20.05.24GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - April 2024

20.05.24GlobeNewswirePress Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

13.05.24GlobeNewswirePress Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty

10.05.24PR NewswireNovavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines

10.05.24GlobeNewswirePress Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

02.05.24GlobeNewswirePress Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations

30.04.24GlobeNewswirePress Release: Annual General Meeting of April 30, 2024

25.04.24GlobeNewswirePress Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance

23.04.24GlobeNewswirePress Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

17.04.24GlobeNewswirePress Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

12.04.24GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - March 2024

08.04.24GlobeNewswireSanofi - AGM 30.04.2024 - Availability of Preparatory documents

22.03.24GlobeNewswirePress Release: Availability of the Q1 2024 Memorandum for modelling purposes

15.03.24GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - February 2024

11.03.24GlobeNewswirePress Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis

24.02.24GlobeNewswirePress Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria

23.02.24GlobeNewswirePress Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

23.02.24GlobeNewswirePress Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation

22.02.24GlobeNewswirePress Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors

20.02.24GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - January 2024

16.02.24GlobeNewswirePress Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)

15.02.24GlobeNewswirePress Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS

05.02.24GlobeNewswirePress Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses

01.02.24GlobeNewswirePress Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee

01.02.24GlobeNewswirePress Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline

25.01.24GlobeNewswirePress Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)

23.01.24GlobeNewswirePress Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

Sanofi News

Sanofi News: auf dieser Seite finden Sie alle Sanofi News und Nachrichten zur Sanofi Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sanofi News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sanofi News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.